Company · ASND
Ascendis Pharma A/S
Nasdaq's symbol directory lists ASND on Nasdaq as “Ascendis Pharma A/S - Ordinary Share”.
In the 12 months to Nov 19, 2026: insiders bought on 1 occasion ($493K); insiders sold on 3 occasions ($6.2M); 1 planned-sale notice; 3 filings by holders of 5% or more.
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG, EVP & Chief Admin Officer sold $5.3M
- Bodenhoff Mads, SVP & PAO sold $811K
- Jean J. Bienaime bought $493K
- HOLTUG LARS sold $62K
Every trade (4)
- SELLPEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG, EVP & Chief Admin Officer sold $5.3M
- SELLBodenhoff Mads, SVP & PAO sold $811K
- SELLHOLTUG LARS sold $62K
- BUYJean J. Bienaime bought $493K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- T. Rowe Price Investment Management, Inc. 12.4%
- FMR LLC 5.2%
- Artisan Partners Asset Management Inc. 4.2%
Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.